Data Analysis Service (DAS)

Data Analysis Service (DAS) provides reports generated and delivered by a team of NanoString scientific leads and supporting analysts/biostaticians.


  • Professional analysis from expert scientists who know NanoString data best
  • Highly consultative
  • Publication-ready figures
  • Fast turn-around time
  • Interactive one-on-one data review

Customizable analysis services are also available.


360 Analysis Reports

Data analysis report for the nCounter® PanCancer IO 360™ Gene Expression Panel

  • Unique 360 view of gene expression for the tumor, microenvironment and immune response
  • Interactive reports prepared by NanoString expert scientists
  • 48 signatures including TIS, 14 signatures measuring immune cell populations and 34 novel signatures measuring important tumor and immune activities
  • Tumor Inflammation Score (TIS) provided for each sample to determine “hot” and “cold” tumors
  • Analysis includes sample signature score in relation to immune response
  • All data undergoes QC and normalization
  • Flexibility to include up to 5 additional user-defined signatures based on IO 360 or Panel Plus genes
  • Standard report currently available for human only


Expedite analysis to insight: 48 signatures provide a multi-faceted view of the tumor immune interplay.

Tumor Immunogenicity Tumor Sensitivity to Immune Attack Inhibitory Immune Mechanisms Stromal Factors Inhibitory Metabolism Anti-Tumor Immune Activity Inhibitory Immune Signaling Immune Cell Population Abundance
Antigen Processing Machinery Apoptosis IDO1 Gene Expression Endothelial Cells Glycolysis Tumor Inflammation Signature (TIS) CTLA4 Gene Expression B Cells NK CD56dim Cells
Antigen Presenting Machinery Expression Loss Tumor Proliferation PD-L1 Gene Expression Stromal Tissue Abundance Hypoxia Cytotoxicity IL10 Gene Expression CD45+ Cells Natural Killer Cell Abundance
Immunoproteasome JAK-STAT Pathway Gene Expression Loss B7-H3 Gene Expression     Interferon Gamma Signaling Inflammatory Chemokines CD8 T Cell T Cells Abundance
MAGE Genes Expression   TGF-Beta Gene Expression     Interferon Signaling Response Myeloid-Derived Inflammatory Signaling Cytotoxic Cells TH1 Cell (TBX21/T-bet) Expression
Loss of Mismatch Repair Gene Expression         Lymphoid Compartment Activity PD-1 Gene Expression Dendritic Cells Treg (FOXP3 Expression)
Hypermutation         MHC Class II Antigen Presentation PD-L2 Gene Expression Exhausted CD8 Cell  
MSI Predictor         Myeloid Compartment Activity TIGIT Gene Expression Macrophage  
            ARG1 Gene Expression Mast Cells  
            NOS2 Gene Expression Neutrophils  

Try the Interactive Demo Report today!

IM_MK2255_Gx Panel Images_FINAL.png

General Information

Individual Signature Analysis

The following signature is available on an à la carte basis:

The Tumor Inflammation Signature (TIS) quantifies the magnitude of a peripherally suppressed, adaptive immune response in the tumor microenvironment. It has been trained and validated by Merck to predict response to single agent Pembrolizumab, independent of tumor cell of origin.

The following signature is available on an à la carte basis:

PAM50 intrinsic breast cancer subtypes used in this analysis defines 4 prototypical subtypes Basal, Her2-Enriched, Luminal B and Luminal A. The clinical and prognostic characteristics of these subtypes are extensively studied. If clinical tumor size is provided, the PAM50 report will also include the Risk of Recurrence (ROR) score. If the number of positive nodes is provided, the PAM50 report will also include Risk Category.

The following signature is available on an à la carte basis:

The Lymphoma Subtyping Test is based on the Leukemia and Lymphoma Molecular Profiling Project Lymph2Cx assay and provides cell of origin data for diffuse large B-cell lymphomas. The LST report includes the Linear Predictor Score (LPS) and the DLBCL cell of origin subtype: GCB, ABC, or Unclassified.

IO 360 Participating CROs:



For Research Use Only. Not for use in diagnostic procedures.